Elanco Animal Health Inc — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Elanco reported Q2 2026 revenue of $1,368M (+10% reported, +8% organic constant currency) driven by blockbuster drug Zenrelia and Credelio Quattro. Adjusted EBITDA was $288M with 21.2% margin. The company raised full-year 2026 revenue guidance to $5.09–$5.14B (from $5.01–$5.09B), raised adjusted EBITDA to $1.01–$1.035B (from $975–$1.005M), and raised adjusted EPS to $1.10–$1.16 (from $1.03–$1.09). Net leverage improved to 3.1x (vs. 3.6x at year-end 2025), with year-end target of ~3.0x.
Why this rating
Broad-based guidance raises on strong innovation execution (Zenrelia, Credelio Quattro) and margin expansion. ~$100M revenue raise and $35M EBITDA raise represent ~1.4% and ~3.5% of company size. Meaningful but not transformational; execution risk remains on pipeline.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.